Cahill Represents Lead Arranger in $575 Million Revolving Credit Facility for Halozyme Therapeutics, Inc.
Date: 08/18/22
Cahill represented the Lead Arranger in connection with an amendment to Halozyme Therapeutics, Inc.’s credit agreement to increase the revolving credit facility by $225,000,000 to $575,000,000. Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes.